Idarucizumab

Idarucizumab, sold under the brand name Praxbind, is a monoclonal antibody used as a reversal agent for dabigatran.[1] Idarucizumab was developed by Boehringer Ingelheim. One study sponsored by the manufacturer found that idarucizumab effectively reversed anticoagulation caused by dabigatran within minutes.[3] It was approved for medical use in the United States and in the European Union in 2015.[4][1][2] Content... [wikipedia]